News und Analysen
![Illumina Welcomes Kathryne Reeves as Chief Marketing Officer](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Illumina Welcomes Kathryne Reeves as Chief Marketing Officer
Illumina (NASDAQ: ILMN) announced today that Kathryne Reeves will join the company as Chief Marketing Officer on September 28, 2020. Reeves brings more than 25 years of marketing and general
![Illumina Welcomes Kathryne Reeves as Chief Marketing Officer](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Illumina Welcomes Kathryne Reeves as Chief Marketing Officer
Illumina (NASDAQ: ILMN) announced today that Kathryne Reeves will join the company as Chief Marketing Officer on September 28, 2020. Reeves brings more than 25 years of marketing and general
![Illumina Welcomes Kathryne Reeves as Chief Marketing Officer](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Illumina Welcomes Kathryne Reeves as Chief Marketing Officer
Illumina (NASDAQ: ILMN) announced today that Kathryne Reeves will join the company as Chief Marketing Officer on September 28, 2020. Reeves brings more than 25 years of marketing and general
![Premier, Inc. Reports Fiscal 2020 Fourth-Quarter and Full-Year Results](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Premier, Inc. Reports Fiscal 2020 Fourth-Quarter and Full-Year Results
Premier, Inc. (NASDAQ: PINC) today reported financial results for the fiscal year (FY) 2020 fourth quarter and full year ended June 30, 2020.
All results presented in this press release reflect
![Ipsen to Present Results From MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP), at ASBMR 2020 Annual Meeting](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Ipsen to Present Results From MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP), at ASBMR 2020 Annual Meeting
Ipsen (Euronext: IPN; ADR: IPSEY) today announced results from the MOVE trial, the first and only multicenter Phase III study in fibrodysplasia ossificans progressiva (FOP), to be presented during
![Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today shared additional Phase 1 safety and immunogenicity data from their ongoing U.S. study of the BNT162 mRNA-based vaccine program against
![Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today shared additional Phase 1 safety and immunogenicity data from their ongoing U.S. study of the BNT162 mRNA-based vaccine program against
![Quidel Concludes Sofia® SARS Antigen Investigation From Vermont](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Quidel Concludes Sofia® SARS Antigen Investigation From Vermont
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has
![Quidel to Update Packaging of Point-of-Care Sofia® SARS Antigen Test for COVID-19 to Include Either Nasal or Nasopharyngeal Swabs](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Quidel to Update Packaging of Point-of-Care Sofia® SARS Antigen Test for COVID-19 to Include Either Nasal or Nasopharyngeal Swabs
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that labeling for
![Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the publication of interim results from its Phase II CONTROL trial of neratinib in the September 2020 Issue (Volume
![Momenta Pharmaceuticals: Nächste Mega-Übernahme im US-Biotechsektor!](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Momenta Pharmaceuticals: Nächste Mega-Übernahme im US-Biotechsektor!
Zuletzt verging kaum ein Tag, an dem nicht irgendeine Mega-Übernahme im US-Biotechsektor vermeldet wurde. So auch heute. Denn heute verkündete Johnson & Johnson die Übernahme von Momenta
![Agilent Reports Third-Quarter Fiscal Year 2020 Financial Results](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Agilent Reports Third-Quarter Fiscal Year 2020 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.26 billion for the third quarter ended July 31, 2020, a decline of 1% compared to the third quarter of 2019 and down 3.1% on a core(
![Premier Inc. Working with AstraZeneca to Reduce Hospitalizations of Patients with Hyperkalemia](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Premier Inc. Working with AstraZeneca to Reduce Hospitalizations of Patients with Hyperkalemia
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, announced today it has reached a significant milestone in its partnership with AstraZeneca, a global, science-led
![Agilent to Expand State-of-the-Art Manufacturing Capacity for Nucleic Acid-Based Therapeutics](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Agilent to Expand State-of-the-Art Manufacturing Capacity for Nucleic Acid-Based Therapeutics
Agilent Technologies Inc. (NYSE: A) today announced it will expand its state-of-the-art production facility in Frederick, Colorado, that develops and manufactures “oligos,” which are short DNA and
![Deciphera Announces Publication of QINLOCK™ (ripretinib) Phase 1 Study Results in Patients with Gastrointestinal Stromal Tumor in Journal of Clinical Oncology](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Deciphera Announces Publication of QINLOCK™ (ripretinib) Phase 1 Study Results in Patients with Gastrointestinal Stromal Tumor in Journal of Clinical Oncology
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced that the Journal of Clinical Oncology has published results from its Phase 1 study of QINLOCK, the Company’s switch-control tyrosine
![Journal of Clinical Oncology Publishes Additional Data from Clovis Oncology’s TRITON2 Clinical Trial Evaluating Rubraca® (rucaparib) for the Treatment of mCRPC in Patients with BRCA1/2 Gene Mutations](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Journal of Clinical Oncology Publishes Additional Data from Clovis Oncology’s TRITON2 Clinical Trial Evaluating Rubraca® (rucaparib) for the Treatment of mCRPC in Patients with BRCA1/2 Gene Mutations
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that data from the Phase 2 TRITON2 study of Rubraca® (rucaparib) for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
![Novocure Announces Expansion of Its Executive Leadership Team](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Novocure Announces Expansion of Its Executive Leadership Team
Novocure (NASDAQ:NVCR) today announced an expansion of its Executive Leadership Team, effective Sept. 1, 2020, intended to further solidify executive leadership in preparation for an anticipated
![Quidel’s Lyra® Direct SARS-CoV-2 Assay Receives Health Canada Authorization](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Quidel’s Lyra® Direct SARS-CoV-2 Assay Receives Health Canada Authorization
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has
![LivaNova to Present Autonomic Regulation Therapy Findings for Heart Failure During European Society of Cardiology Congress 2020](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
LivaNova to Present Autonomic Regulation Therapy Findings for Heart Failure During European Society of Cardiology Congress 2020
LivaNova PLC (NASDAQ:LIVN) a market-leading medical technology and innovation company, today announced it will present a poster at the European Society of Cardiology (ESC) Congress 2020 on the
![Dexcom Appoints Karen Dahut to Board of Directors](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Dexcom Appoints Karen Dahut to Board of Directors
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the appointment of Karen Dahut to its Board of Directors, effective immediately.
Ms
![Dexcom Appoints Karen Dahut to Board of Directors](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Dexcom Appoints Karen Dahut to Board of Directors
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the appointment of Karen Dahut to its Board of Directors, effective immediately.
Ms
![Lantheus Holdings, Inc. Announces FDA Approval of VIALMIX® RFID Device for DEFINITY®](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Lantheus Holdings, Inc. Announces FDA Approval of VIALMIX® RFID Device for DEFINITY®
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture